Dermata Therapeutics Warrant
DRMAW
DRMAW was delisted on the 17th of August, 2026.
4 hedge funds and large institutions have $7.7K invested in Dermata Therapeutics Warrant in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.
13,394% more capital inflows, than outflows
Capital inflows: $4.72K | Capital outflows: $35
9.48% more ownership
Funds ownership: 2.13% → 11.61% (+9.5%)
0% more funds holding
Funds holding: 4 → 4 (0)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
+$4.72K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$35 |
DRMAW Hedge Fund Activity: Q4 2023 in Review
4 of the 6,873 institutional investors tracked by Wall St. Rank reported a position in Dermata Therapeutics Warrant (DRMAW) for Q4 2023, worth a combined $7.7K — down 44% from $13.7K a quarter earlier.
Fund positioning in DRMAW was balanced in Q4 2023: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was Armistice Capital, adding an estimated $4.72K. The largest seller was UBS Group, cutting an estimated $35.
- 4 institutional investors held Dermata Therapeutics Warrant (DRMAW) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $7.7K of Dermata Therapeutics Warrant stock for Q4 2023, down 44% quarter-over-quarter.
- 0 funds opened new Dermata Therapeutics Warrant positions in Q4 2023 and 0 closed out.
- The largest Dermata Therapeutics Warrant buyer in Q4 2023 was Armistice Capital, an estimated $4.72K added.
- The largest Dermata Therapeutics Warrant seller in Q4 2023 was UBS Group, an estimated $35 sold.
Based on aggregated 13F filings for Q4 2023.